MedTrace Logo

Supplemental Oxygen in Pulmonary Fibrosis

NCT01961362 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2020-02-25

Study results available
· View outcomes & findings →

Summary

To enhance understanding of supplemental oxygen-its utility in and adoption by patients with pulmonary fibrosis-by examining how patients perceive it and by determining how perceptions and patient-centered outcome measures change from before to after supplemental oxygen is prescribed.

Conditions

Sponsors & Collaborators

  • Pulmonary Fibrosis Foundation

    collaborator OTHER

  • Patient-Centered Outcomes Research Institute

    collaborator OTHER

  • National Jewish Health

    lead OTHER

Principal Investigators

  • Jeff Swigris, DO, MS · National Jewish Health

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01961362 on ClinicalTrials.gov